Table 2.
Ongoing RCTs evaluating combination therapies in patients with NAFLD.
| Medications; Date of Enrollment Initiation (Date/Month/Year) 1 | Disease(s) | Estimated Enrollment (N) | Duration (Months) | Groups | Trial Identifier |
|---|---|---|---|---|---|
| Rosuvastatin and ezetimibe; 14 May 2018 | NAFLD/Dyslipidemia | 70 | 6 | Rosuvastatin vs. rosuvastatin + ezetimibe | NCT03434613 |
| Tropifexor and cenicriviroc; 11 September 2018 | NASH | 200 | 12 | Tropifexor vs. cenicriviroc vs. tropifexor + cenicriviroc | NCT03517540 |
| Pioglitazone and empagliflozin; 19 December 2018 | NAFLD/T2DM | 60 | 6 | Pioglitazone vs. empagliflozin vs. pioglitazone + empagliflozin | NCT03646292 |
| Garlic and silymarin and curcumin; 1 July 2019 | NAFLD | 60 | 3 | Garlic + silymarin + curcumin vs. placebo | IRCT20190602043787N1 |
| Tropifexor and licogliflozin; 11 December 2019 | NASH | 380 | 12 | Tropifexor + licogliflozin vs. tropifexor + placebo vs. licogliflozin + placebo vs. placebo + placebo | NCT04065841 |
| Saroglitazar and vitamin E; 16 December 2019 | NAFLD | 200 | 6 | Saroglitazar vs. vitamin E vs. saroglitazar + vitamin E vs. lifestyle modifications | CTRI/2019/12/022339 |
| Elobixibat and cholestyramine; 29 January 2020 | NAFLD/NASH | 100 | 4 | Elobixibat + cholestyramine vs. elobixibat + placebo vs. placebo + cholestyramine vs. placebo + placebo | NCT04235205 |
| LYS006 and tropifexor; 4 June 2020 | NAFLD/NASH | 250 | 5 | LYS006 vs. LYS006 + tropifexor | NCT04147195 |
| MET409 and empagliflozin; 15 December 2020 | NASH/T2DM | 120 | 3 | MET409 vs. placebo vs. MET409 + empagliflozin vs. placebo + empagliflozin | NCT04702490 |
| Empagliflozin and semaglutide; 26 March 2021 | NAFLD/NASH/T2DM | 192 | 12 | Empagliflozin + semaglutide vs. empagliflozin + placebo vs. placebo + placebo | NCT04639414 |
| Luseogliflozin and semaglutide; 29 July 2021 | NASH/T2DM | 60 | 12 | Luseogliflozin + semaglutide vs. semaglutide | jRCTs061210009 |
1 Studies are sorted according the date of enrollment. Abbreviations: NAFLD—nonalcoholic fatty liver disease; NASH—nonalcoholic steatohepatitis; RCT—randomized clinical trials; T2DM—type 2 diabetes mellitus.